Immunome (IMNM) AI Stock Analysis

• Market Cap: $945.82M
• Dividend Yield: N/A
• Average Volume (3M): 1.05M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: -13.76%
• EPS Growth: 57.73%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.52
• Shares Outstanding: 87,012,330
• 10 Day Avg. Volume: 987,273
• 30 Day Avg. Volume: 1,053,320
• PEG Ratio: -0.04
• Price to Book (P/B): 2.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.49
• Enterprise Value/Market Cap: 0.51
• Enterprise Value/Revenue: 11.69
• Enterprise Value/Gross Profit: 43.71
• Enterprise Value/Ebitda: -0.94
• 1Y Price Target: $25.50
• Price Target Upside: 134.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 52 Neutral
• Price Target: $10.00 ▼(-8.00%Downside)

Immunome's overall stock score is primarily impacted by its financial difficulties, with persistent operational losses weighing heavily. The technical analysis offers some optimism with short-term positive trends. However, the negative valuation metrics, particularly the negative P/E ratio, reflect significant profitability challenges.

Positive Factors

Commercialization Strategy

The company intends on commercializing varegacestat in the US, Canada, and Europe, with external distributors in LATAM and Middle East, as well as partner(s) in Asia.

Drug Efficacy

IMNM's asset varegacestat has shown increased efficacy in Phase 2 data compared to the first FDA-approved medicine for desmoid tumors.

Financial Position

The company has a strong cash position with $317.3 million in cash and cash equivalents, providing a cash runway into 2027.

Negative Factors

Data Readout Uncertainty

The company has not guided to a timeline for a data readout from the ongoing Phase 1 trial evaluating IM-1021.

Manufacturing and Pharmacology

The company will perform further manufacturing and pharmacology work to support an eventual NDA filing.

Immunome Business Overview & Revenue Model

Company Description

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

How the Company Makes Money

Immunome makes money primarily through the development and commercialization of its proprietary antibody-based therapeutics. The company generates revenue through strategic partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve milestone payments and royalties from the commercialization of co-developed products. Immunome may also secure funding through government grants and research funding to support its R&D efforts. Additionally, as its pipeline products advance through clinical trials and potentially reach regulatory approval, Immunome can generate significant revenues from product sales.

Immunome Financial Statement Overview

Summary

Immunome faces substantial financial difficulties, with persistent losses impacting profitability and cash flow. Despite a strong equity position, the negative profitability metrics and cash flow challenges weigh heavily on its financial performance score.

Income Statement

Immunome's income statement reflects significant challenges, with consistent net losses and negative EBIT and EBITDA margins over the periods reported. Despite some revenue growth from 2024 to TTM (Trailing-Twelve-Months), the company operates with negative profitability metrics, indicating ongoing operational difficulties.

Balance Sheet

The balance sheet shows a strong equity base with a favorable debt-to-equity ratio, suggesting financial stability. However, the company’s high cash position is offset by recurring net losses, which could pressure equity if operations do not improve.

Cash Flow

Immunome's cash flow statement highlights negative operating cash flows, though financing activities have supported liquidity. Free cash flow is persistently negative, which is concerning for long-term sustainability unless the trend reverses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.04M	14.02M	0.00	0.00	0.00
Gross Profit	9.04M	14.02M	-631.00K	-755.00K	-755.00K
EBITDA	-151.35M	-28.00M	-36.27M	-23.95M	-17.04M
Net Income	-292.96M	-106.81M	-37.51M	-24.47M	-17.12M
Balance Sheet
Total Assets	240.24M	148.54M	24.05M	57.92M	44.52M
Cash, Cash Equivalents and Short-Term Investments	217.30M	138.14M	20.32M	49.23M	39.77M
Total Debt	4.83M	1.65M	293.00K	317.00K	613.00K
Total Liabilities	59.08M	28.66M	7.39M	9.74M	3.18M
Stockholders Equity	181.16M	119.88M	16.65M	48.19M	41.34M
Cash Flow
Free Cash Flow	-117.97M	-8.40M	-28.94M	-18.30M	-12.72M
Operating Cash Flow	-110.79M	-7.57M	-28.69M	-18.23M	-12.13M
Investing Cash Flow	-85.06M	-30.48M	-248.00K	-79.00K	-586.00K
Financing Cash Flow	240.53M	116.41M	32.00K	27.77M	49.94M

Immunome Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.87
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNM, the sentiment is Positive. The current price of 10.87 is above the 20-day moving average (MA) of 9.54, above the 50-day MA of 9.11, and above the 200-day MA of 9.88, indicating a bullish trend. The MACD of 0.61 indicates Negative momentum. The RSI at 64.62 is Neutral, neither overbought nor oversold. The STOCH value of 86.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMNM.

Immunome Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$16.95B	5.65	-7.44%	2.87%	11.55%	-28.15%
PHAR	60 Neutral	$692.95M	―	-6.33%	―	23.92%	-27.69%
TRVI	55 Neutral	$937.67M	―	-55.12%	―	―	-60.26%
IMNM	52 Neutral	$945.82M	―	-69.21%	―	-13.76%	57.73%
PRTA	51 Neutral	$359.56M	―	-23.46%	―	54.55%	36.41%
DNTH	51 Neutral	$700.77M	―	-28.73%	―	189.31%	51.03%
KALV	45 Neutral	$728.33M	―	-121.50%	―	―	-18.75%

Immunome Corporate Events

Immunome Elects New Directors at Annual Meeting

Immunome, Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025, where stockholders elected Isaac Barchas and Jean-Jacques Bienaimé as Class II Directors to serve until the 2028 Annual Meeting. Additionally, stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (IMNM) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Immunome stock, see the IMNM Stock Forecast page.

Immunome Expands Share Reserve in Inducement Plan

On May 8, 2025, Immunome‘s Board of Directors approved an amendment to increase the number of shares reserved under its 2024 Inducement Plan, aimed at attracting new employees. The company reported its first-quarter 2025 financial results, highlighting a net loss of $41.6 million and a cash position expected to fund operations into 2027. Immunome is progressing with its clinical trials, including the Phase 3 RINGSIDE trial for varegacestat and Phase 1 trials for IM-1021 and IM-3050, positioning itself as a leader in targeted cancer therapies.

The most recent analyst rating on (IMNM) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Immunome stock, see the IMNM Stock Forecast page.